Patients can obtain a customized dosage that is adjusted to their specific needs
In the broader obesity studies that made these medicines familiar, semaglutide reached 14.9% mean weight loss at 68 weeks in STEP-1 (n=1,961) and tirzepatide reached 20.9% at 72 weeks at the highest dose in SURMOUNT-1 (n=2,539)
CrossRef Liver cirrhosis in metabolic dysfunction-associated steatohepatitis Donghyun Ko, Do Han Kim, Pojsakorn Danpanichkul, Masahito Nakano, Chitchai Rattananukrom, Karn Wijarnpreecha, Cheng Han Ng, Mark D Muthiah Gastroenterology Report .2025;[Epub] CrossRef From liver to limb: Exploring the association between fatty liver disease and peripheral artery diseaseA systematic review Vera Ciornolutchii, Abdulrahman Ismaiel, Jennifer Bogdan, StefanLucian Popa, Teodora SurdeaBlaga, Dan L
For larger changes or for people with metabolic disease, six months gives a stronger picture
PMC 8944412